

CONVENING NOTICE

This is the convening notice for the extraordinary general meeting of shareholders of Crown LiquidationCo N.V. in liquidatie (formerly: Centogene N.V.) (the "**Company**") to be held on Friday May 30, 2025 at 2:00 pm CET at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "**EGM**").

The agenda for the EGM is as follows:

1. Opening
2. Discussion of the Dutch statutory annual report for the financial year 2023 (*discussion item*)
3. Adoption of the Dutch statutory annual accounts for the financial year 2023 (*voting item*)
4. Extension of the period for drawing up the Dutch statutory annual accounts and board report for the financial year ended December 31, 2024 (*voting item*)
5. Final release of the current and former managing directors and liquidators from liability for the exercise of their duties (*voting item*)
6. Final release of the current and former supervisory directors from liability for the exercise of their duties (*voting item*)
7. Reappointment of Mr. Hubert Birner as supervisory director of the Company (*voting item*)
8. Closing

No business shall be voted on at the EGM, except for the voting items as included in the above-mentioned agenda.

The record date for the EGM is May 2, 2025 (the "**Record Date**"). Those who are shareholders of the Company or who otherwise have voting rights and/or meeting rights with respect to ordinary shares in the Company's capital, in each case as at close of business on the Record Date (after processing of all book-entry transfers and other relevant changes relating to the ordinary shares in the Company's capital), and who are recorded as such in (i) the Company's shareholders' register and/or (ii) the register maintained by the Company's U.S. transfer agent may attend and, if relevant, vote at the EGM ("**Eligible Participants**"), irrespective of changes to their shareholdings or rights after the Record Date.

Eligible Participants who wish to attend the EGM, in person or represented by proxy, must register for the EGM by sending notice to the Company of their identity and intention to attend the EGM

(an "**Attendance Notice**") ultimately by 6:00 am CET on May 26, 2025 (the "**Cut-off Time**"). Eligible Participants must enclose with their Attendance Notice a proof of their ownership of (or other entitlement to voting rights with respect to) the relevant shares in the Company's capital as at the Record Date that are being registered for the EGM. Eligible Participants who have not complied with these requirements may be refused entry to the EGM.

Eligible Participants who have registered for the EGM in accordance with the procedures outlined above may have themselves represented at the EGM through the use of a written or electronically recorded proxy. A proxy form for granting a written proxy can be downloaded from the Company's investor website (<https://investors.centogene.com/>). Proxyholders must present a copy of their proxies upon entry to the EGM, failing which the proxyholder concerned may be refused entry to the EGM.

Those who beneficially own shares in the Company's capital through a bank, broker, trustee, financial institution or other intermediary on the Record Date (the "**Beneficial Owners**") should contact their bank, broker, trustee, financial institution or other intermediary through which the underlying shares are beneficially owned for further information on how to have those shares voted at the EGM.

Any Attendance Notice, proof of ownership, written proxy or other materials to be sent to the Company as part of the procedures described above must be provided ultimately by the Cut-off Time via regular mail or e-mail to:

Crown LiquidationCo N.V. in liquidatie
c/o Investor Relations
Am Strande 7
18055 Rostock
Germany
[*\(investor.relations@centogene.com\)*](mailto:investor.relations@centogene.com)

Any Attendance Notice, proof of ownership, written proxy or other materials received by the Company after the Cut-off Time may be ignored by the Company.

EXPLANATORY NOTES TO THE AGENDA

Except as otherwise defined in the convening notice to which these explanatory notes pertain, the following definitions shall apply in these explanatory notes:

Articles of Association	The Company's articles of association.
Company	Crown LiquidationCo N.V. in liquidatie (formerly: Centogene N.V.)
Liquidator	A liquidator of the Company.
Management Board	The Company's management board.
Managing Director	A member of the Management Board.
Supervisory Board	The Company's supervisory board.
Supervisory Director	A member of the Supervisory Board.

2. Discussion of the Dutch statutory annual report for the financial year 2023 (*discussion item*)

The Management Board has prepared the Company's Dutch statutory annual report for the financial year 2023. This annual report has been approved by the Supervisory Board and has been made available on the Company's website and at the Company's office address.

3. Adoption of the Dutch statutory annual accounts for the financial year 2023 (*voting item*)

The Management Board has prepared the Company's Dutch statutory annual accounts for the financial year 2023. These annual accounts have been approved by the Supervisory Board and have been made available on the Company's website and at the Company's office address. It is proposed that these annual accounts be adopted.

4. Extension of the period for drawing up the Dutch statutory annual accounts and board report for the financial year ended December 31, 2024 (*voting item*)

It is proposed to extend the period for drawing up and making available for inspection at the Company's offices the Dutch statutory annual accounts and board report for the financial year ended December 31, 2024 by a maximum period of five months, as referred to in Section 2:101 of the Dutch Civil Code, in view of special circumstances.

5. Final release of the current and former managing directors and liquidators from liability for the exercise of their duties (*voting item*)

It is proposed that the current and former Managing Directors and Liquidators be released from liability for the exercise of their duties. The scope of this release from liability extends to the exercise of their respective duties insofar as these are reflected in the Company's Dutch statutory annual reports and/or annual accounts or in other public disclosures or communications to the General Meeting.

6. Final release of the current and former supervisory directors from liability for the exercise of their duties (*voting item*)

It is proposed that the current and former Supervisory Directors be released from liability for the exercise of their duties. The scope of this release from liability extends to the exercise of their respective duties insofar as these are reflected in the Company's Dutch statutory annual reports and/or annual accounts or in other public disclosures or communications to the General Meeting.

7. Reappointment of Mr. Hubert Birner as supervisory director of the Company (*voting item*)

The Supervisory Board has made a binding nomination to reappoint Mr. Hubert Birner as a supervisory director of the Company. Mr. Birner is proposed for reappointment for a period ending at the end of the liquidation process of the Company.

Mr. Birner (age 58) was appointed as Supervisory Director upon the Company's IPO in 2019. Mr. Birner joined the Centogene's supervisory board as chairman from July 2017 to March 30, 2019, and as vice-chairman from April 1, 2019, to March 16, 2020. Mr. Birner is responsible for TVM Capital Life Science's overall investment strategy and global fund operations in Europe and North America. He currently serves as chairman of the board of directors of Leon-nanodrugs GmbH and AL-S Pharma AG. Mr. Birner previously served on the board of Acer Therapeutics, Argos Therapeutic, Horizon Pharma, Inc., Bioxell SA, Evotec AG, Jerini AG, Noxxon Pharma, Probiodrug AG, Proteon Therapeutics Inc. and SpePharm Holdings BV. Prior to his current tenure, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca Agrochemicals. Mr. Birner joined Zeneca from McKinsey & Company's European Health Care and Pharmaceutical practice and as Assistant Professor for biochemistry at the Ludwig-Maximilian-University (LMU), following his summa cum laude doctoral degree in biochemistry at LMU; his doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases. Mr. Birner also holds an MBA from Harvard Business School.

Mr. Birner does not hold any shares in the Company's share capital.

Mr. Birner has been nominated for his experience, background and skills, and in order to maintain continuity in the supervision of the Company's liquidation process.

o O o